O’Brien, Evan S. http://orcid.org/0000-0002-2260-7722
Rangari, Vipin Ashok http://orcid.org/0000-0002-9721-6195
El Daibani, Amal
Eans, Shainnel O.
Hammond, Haylee R.
White, Elizabeth
Wang, Haoqing
Shiimura, Yuki
Krishna Kumar, Kaavya http://orcid.org/0000-0003-2283-4033
Jiang, Qianru
Appourchaux, Kevin http://orcid.org/0000-0001-9853-3347
Huang, Weijiao
Zhang, Chensong
Kennedy, Brandon J. http://orcid.org/0000-0003-1892-8926
Mathiesen, Jesper M.
Che, Tao http://orcid.org/0000-0002-1620-3027
McLaughlin, Jay P. http://orcid.org/0000-0001-9851-9342
Majumdar, Susruta http://orcid.org/0000-0002-2931-3823
Kobilka, Brian K. http://orcid.org/0000-0001-5958-3990
Article History
Received: 6 July 2023
Accepted: 21 May 2024
First Online: 3 July 2024
Competing interests
: B.K.K. is a founder and consultant for ConfometRx. S.M. is a founder of Sparian Biosciences. E.S.O., K.K.K., V.A.R., S.M. and B.K.K. have filed a patent around the new NAM compound acting through µOR. B.J.K. is an employee of Lotus Separations. The remaining authors declare no other competing interests.